Company intelligence / Profile preview
Bio-Thera Solutions, Ltd.
Guangzhou, Chinabio-thera.com ↗
- Ownership
- Public · 688177
- Employees
- ~1167
- Development stage
- Commercial
01
Overview
The company has multiple approved products including QLETLI® (adalimumab biosimilar), POBEVCY® (bevacizumab biosimilar), TOFIDENCE™, BETAGRIN®, and Avzivi® (bevacizumab-tnjn)
- Therapeutic areas
- GastroenterologyCardiovascularRheumatologyOphthalmologyImmunologyDermatologyOncology
- Modalities
- Antibody drugsbiosimilarsbi-functional fusion proteins
- Industry
- Biotech
02
Drug pipeline
36 assets35 more assets in the full pipeline.
03
Partnerships
STADA (for BAT2506)
Beyond the preview
Go deeper on Bio-Thera Solutions, Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bio-Thera Solutions, Ltd..